Abstract
Background Since the United Network for Organ Sharing (UNOS) allocation system change patients listed for orthotopic heart transplant (OHT) are more likely to be on temporary mechanical circulatory support (tMCS). Limited sex specific data exits for use and outcomes of tMCS since the allocation change.
Methods We queried the UNOS registry for patients listed for OHT on tMCS from October 1, 2015 to June 28, 2023, comparing baseline characteristics and outcomes between sexes pre- and post-allocation change.
Results Women comprised 23% of patients listed for OHT on tMCS before and after the allocation change, despite similar cardiac index (CI) compared with men (pre: 2.03 vs 2.09 L/min m2 p=0.21; post: 1.92 vs 1.92 L/min m2 p=0.89). Women were significantly younger (54 vs 57 years; p<0.001), had lower BMI (26.9 vs 27.2; p 0.006), were more likely to be on intra-aortic balloon pump (IABP) (67% vs 61% p <0.001) and had shorter waitlist times (13 vs 16 days; p <0.001). Waitlist mortality decreased similarly for both sexes (3.6% vs 3.8%; p= 0.7). There was no significant difference in 1-year post-transplant survival between the sexes in either era (HR: 0.9, 95% CI: 0.76, 1.06 p=0.2), however, 1-year post-transplant survival improved overall for patients bridged with tMCS post allocation change independent of sex (HR 0.70 (95% CI: 0.54 to 0.90; p=0.005).
Conclusion Despite an increase in the use of tMCS as a bridge to OHT since the UNOS allocation change, women comprise less than a quarter of patients listed on tMCS despite similar CI, suggesting possible underuse in women. Notably, for those bridged to OHT in the post allocation era, waitlist mortality has improved for both sexes and 1-year post-transplant survival has also improved independent of sex.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Atrium Health (IRB #02-21-06E)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Sources of Funding: None
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos